Most relevant findings showed that in a phase Ib study with 24 patients affected by advanced cervical squamous cell cancer and PD-L1 expression in ≥1% of tumor or stromal cells, pembrolizumab was well-tolerated and showed promising anti-tumor activity (Clinical trial information: NCT02054806) (60), while its clinical benefit was investigated in the phase 2 KEYNOTE-158 trial. Here, CD274 is linked to cervical squamous cell carcinoma.